These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29383855)

  • 1. Therapeutic applications of group I intron-based trans-splicing ribozymes.
    Lee CH; Han SR; Lee SW
    Wiley Interdiscip Rev RNA; 2018 May; 9(3):e1466. PubMed ID: 29383855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group I Intron-Based Therapeutics Through Trans-Splicing Reaction.
    Lee CH; Han SR; Lee SW
    Prog Mol Biol Transl Sci; 2018; 159():79-100. PubMed ID: 30340790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trans-splicing with the group I intron ribozyme from Azoarcus.
    Dolan GF; Müller UF
    RNA; 2014 Feb; 20(2):202-13. PubMed ID: 24344321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing.
    Sullenger BA; Cech TR
    Nature; 1994 Oct; 371(6498):619-22. PubMed ID: 7935797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA reprogramming of alpha-mannosidase mRNA sequences in vitro by myxomycete group IC1 and IE ribozymes.
    Fiskaa T; Lundblad EW; Henriksen JR; Johansen SD; Einvik C
    FEBS J; 2006 Jun; 273(12):2789-800. PubMed ID: 16817905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.
    Byun J; Lan N; Long M; Sullenger BA
    RNA; 2003 Oct; 9(10):1254-63. PubMed ID: 13130139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA as a drug target: recent patents on the catalytic activity of trans-splicing ribozymes derived from group I intron RNA.
    Johnson IM
    Recent Pat DNA Gene Seq; 2010 Jan; 4(1):17-28. PubMed ID: 20218956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterodimerization of Group I Ribozymes Enabling Exon Recombination through Pairs of Cooperative trans-Splicing Reactions.
    Tanaka T; Hirata Y; Tominaga Y; Furuta H; Matsumura S; Ikawa Y
    Chembiochem; 2017 Aug; 18(16):1659-1667. PubMed ID: 28556398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-splicing ribozymes for targeted gene delivery.
    Köhler U; Ayre BG; Goodman HM; Haseloff J
    J Mol Biol; 1999 Feb; 285(5):1935-50. PubMed ID: 9925776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating the splicing activity of Tetrahymena ribozyme via RNA self-assembly.
    Hasegawa S; Rao J
    FEBS Lett; 2006 Mar; 580(6):1592-6. PubMed ID: 16472807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs made of RNA: development and application of engineered RNAs for gene therapy.
    Drude I; Dombos V; Vauléon S; Müller S
    Mini Rev Med Chem; 2007 Sep; 7(9):912-31. PubMed ID: 17897081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Experimental Evolution of trans-Splicing Group I Intron Ribozymes.
    Müller UF
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28045452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective expression of transgene using hypoxia-inducible trans-splicing group I intron ribozyme.
    Kim SJ; Lee SW
    J Biotechnol; 2014 Dec; 192 Pt A():22-7. PubMed ID: 25312327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional and target-specific transgene induction through RNA replacement using an allosteric trans-splicing ribozyme.
    Kim J; Jeong S; Kertsburg A; Soukup GA; Lee SW
    ACS Chem Biol; 2014 Nov; 9(11):2491-5. PubMed ID: 25265474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vivo selection method to optimize trans-splicing ribozymes.
    Olson KE; Müller UF
    RNA; 2012 Mar; 18(3):581-9. PubMed ID: 22274958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic applications of ribozymes.
    Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
    Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
    Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of a trans-splicing ribozyme for restoring EGFP truncation mutation].
    Li B; Xiong YQ; Tu HB; Liu QC; Zou DT; Zhou WQ; Chen YY
    Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):748-53. PubMed ID: 16285516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA reprogramming and repair based on trans-splicing group I ribozymes.
    Fiskaa T; Birgisdottir AB
    N Biotechnol; 2010 Jul; 27(3):194-203. PubMed ID: 20219714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.